RET and colorectal neoplasm: Given that ZD6474 is a multi-tyrosine kinase inhibitor that targets VEGFR, RET, and EGFR, and that EGFR signalling plays pivotal roles in colorectal tumour growth, disease progression, and therapy resistance, we sought to determine the extent to which the activation of EGFR might be responsible for accelerating tumourigenesis driven by TGFβ-pathway activation.